Holen Sie sich die Stockscreener-App
5.98
4.91%
0.28
Vorhandelsmarkt:
5.98
Schlusskurs vom Vortag:
$5.70
Offen:
$5.69
24-Stunden-Volumen:
2.84M
Relative Volume:
1.64
Marktkapitalisierung:
$792.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.07M
KGV:
-20.62
EPS:
-0.29
Netto-Cashflow:
$-31.85M
1W Leistung:
+5.28%
1M Leistung:
-5.30%
6M Leistung:
+37.16%
1J Leistung:
+123.13%
1-Tages-Spanne:
$5.53
$6.075
1-Wochen-Bereich:
$5.41
$6.075
52-Wochen-Spanne:
$2.36
$7.48
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie TRVI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
5.98 | 792.62M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Bestätigt | Needham | Buy |
| 2025-03-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Bestätigt | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-30 | Eingeleitet | Raymond James | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Trevi Therapeutics Stockholders Approve Key Amendments - TipRanks
Leerink Partnrs Issues Optimistic Estimate for TRVI Earnings - Defense World
Oppenheimer Raises Price Target for Trevi Therapeutics by $3 - MSN
Squarepoint Ops LLC Acquires Shares of 14,059 Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - Eastern Progress
WilmerHale Advises Trevi Therapeutics, Inc. in $115 Million Public Offering - WilmerHale
Two Sigma Advisers LP Invests $66,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Two Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLC - Defense World
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Trevi Therapeutics Closes Public Offering - MarketScreener
Trevi Therapeutics Announces Closing of $115 Million Underwritte - GuruFocus
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares | TRVI Stock News - GuruFocus
Trevi Therapeutics Secures Massive $115M Funding: Investors Rush to Back Chronic Cough Treatment Developer - Stock Titan
Trevi Therapeutics Announces Pricing of $100 Million Underwritte - GuruFocus
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Sold by BNP Paribas Financial Markets - Defense World
Ameriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics Prices $100 Mln Public Offering Of Common Stock - Nasdaq
Trevi Therapeutics Announces Public Offering Pricing - TipRanks
Trevi Therapeutics IncExpects Cash Resources To Fund Operations Into 2029 - marketscreener.com
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - Eastern Progress
Trevi Therapeutics Announces Proposed Public Offering of Common Stock - Longview News-Journal
Trevi Therapeutics Prices $100 Million Common Stock Offering - marketscreener.com
ProShare Advisors LLC Buys 9,589 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Biotech Trevi Therapeutics Secures Major $100M Financing Through Stock Offering - Stock Titan
Trevi Therapeutics Announces Pricing Of $100 Million Underwritten Offering Of Common Stock - marketscreener.com
H.C. Wainwright maintains Trevi Therapeutics stock rating following trial results - Investing.com Canada
Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results - Insider Monkey
Stifel reiterates buy rating for Trevi Therapeutics stock after study results - Investing.com Canada
Oppenheimer Adjusts Price Target on Trevi Therapeutics to $23 From $20, Maintains Outperform Rating - marketscreener.com
Trevi Therapeutics stock soars to 52-week high of $7.43 By Investing.com - Investing.com South Africa
Trevi Therapeutics launches $100 million stock offering By Investing.com - Investing.com South Africa
Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at D. Boral Capital - Defense World
Trevi Therapeutics stock soars to 52-week high of $7.43 - Investing.com India
Trevi Therapeutics Terminates ATM Prospectus with Leerink - TipRanks
Oppenheimer raises Trevi Therapeutics stock price target to $23 By Investing.com - Investing.com UK
Trevi Therapeutics launches $100 million stock offering - Investing.com Australia
Trevi Therapeutics Plans $100 Million Stock Sale; Shares Sliding in After-Hours Trade - marketscreener.com
Oppenheimer Boosts Trevi Therapeutics (TRVI) Price Target to $23 | TRVI Stock News - GuruFocus
Trevi Therapeutics (TRVI) Receives "Buy" Rating from D. Boral Capital | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Proposed Public Offering Of Common Stock - marketscreener.com
Trevi Therapeutics (TRVI) Launches $100M Public Offering | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Proposed Public Offering of Common Stock | TRVI Stock News - GuruFocus
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients - Benzinga
trevi therapeutics reports positive results from phase 2b cough trial By Investing.com - Investing.com Australia
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Trevi Therapeutics Inc-Aktie (TRVI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SCIASCIA THOMAS | Chief Scientific Officer |
Mar 25 '25 |
Sale |
6.60 |
2,631 |
17,365 |
221,373 |
| GOOD JENNIFER L | President & CEO |
Mar 21 '25 |
Option Exercise |
1.43 |
5,263 |
7,526 |
218,576 |
| GOOD JENNIFER L | President & CEO |
Mar 21 '25 |
Sale |
6.58 |
5,263 |
34,625 |
213,313 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):